How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,657 results for

Fractional Excretion of Sodium

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. Heart Disease and Stroke Statistics

behavior. Although adult television and tablet use has decreased modestly in recent years, adult smartphone use increased from the 2012 to 2014 period to 2017 by >1 hour each day. Nutrition (Chapter 5) In a 2013 to 2014 nationally representative sample of 827 nonpregnant, noninstitutionalized US adults, estimated mean sodium intake by 24-hour urinary excretion was 4205 mg/d for males and 3039 mg/d for females. In a diverse sample of 450 US adults in 3 geographic locations, ≈70% of sodium was added (...) associated with a significant improvement in Healthy Eating Index-2010 score (3.7 higher Healthy Eating Index points; 95% CI, 0.6–6.9). By contrast, participation in the Supplemental Nutrition Assistance Program (SNAP), which does not regulate nutritional quality, was associated with less healthy household purchases (15–20 more calories from SSBs per person per day, 174–195 more milligrams of sodium per person per day, and 0.52 fewer grams of fiber per person per day). Overweight and Obesity (Chapter 6

Full Text available with Trip Pro

2019 American Heart Association

162. Handbook on tuberculosis laboratory diagnostic methods in the European Union

Sodium dodecyl sulfate SNP Single nucleotide polymorphism SOP Standard operating procedures TB Tuberculosis TST Tuberculin skin test UKAS United Kingdom Accreditation Service UK NEQAS UKAS accredited proficiency testing provider No. 4715 VNTR Variable number tandem repeat ZN Ziehl-Neelsen (staining method) Handbook on tuberculosis laboratory diagnostic methods in the European Union – Updated 2018 TECHNICAL REPORT 6 Background and introduction Francis Drobniewski Tuberculosis (TB) is a major cause

2018 European Centre for Disease Prevention and Control - Technical Guidance

163. ESC/ESH Management of Arterial Hypertension

and diastolic blood pressure treatment targets3052 7.3.2 Blood pressure targets in specific subgroups of hypertensive patients3052 7.4 Treatment of hypertension3054 7.4.1 Lifestyle changes3054 7.4.2 Dietary sodium restriction3054 7.4.3 Moderation of alcohol consumption3055 7.4.4 Other dietary changes3055 7.4.5 Weight reduction3055 7.4.6 Regular physical activity3056 7.4.7 Smoking cessation3056 7.5. Pharmacological therapy for hypertension3056 7.5.1 Drugs for the treatment of hypertension3056 7.5.2 (...) Electrocardiogram eGFR Estimated glomerular filtration rate ELSA European Lacidipine Study on Atherosclerosis ENaC Epithelial sodium channel ESC European Society of Cardiology ESH European Society of Hypertension FEVER Felodipine Event Reduction HAS-BLED Hypertension, Abnormal renal/liver function (1 point each), Stroke, Bleeding history or predisposition, Labile INR, Elderly (>65), Drugs/alcohol concomitantly (1 point each) HbA1c Haemoglobin A1c HBPM Home blood pressure monitoring HDL-C HDL cholesterol HELLP

Full Text available with Trip Pro

2018 European Society of Cardiology

164. Management of Cardiovascular Diseases during Pregnancy

Calcium channel blocker CI Confidence interval CO Cardiac output CoA Coarctation of the aorta CPG Committee for Practice Guidelines CT Computed tomography CVD Cardiovascular disease DBP Diastolic blood pressure DCM Dilated cardiomyopathy DES Drug-eluting stent DVT Deep vein/venous thrombosis ECG Electrocardiogram EF Ejection fraction ESC European Society of Cardiology FDA US Food and Drug Administration HCM Hypertrophic cardiomyopathy HF Heart failure HFrEF Heart failure with reduced ejection fraction (...) 5-HT1A 5-hydroxytryptamine (serotonin) HTAD Heritable thoracic aortic disease ICD Implantable cardioverter-defibrillator ICU Intensive care unit IE Infective endocarditis INR International normalized ratio i.v. Intravenous KLH Keyhole limpet haemocyanin LMWH Low molecular weight heparin LQTS Long QT syndrome LV Left ventricular LVEF Left ventricular ejection fraction MCS Mechanical circulatory support mGy Milligray MI Myocardial infarction MR Mitral regurgitation MRA Mineralocorticoid receptor

Full Text available with Trip Pro

2018 European Society of Cardiology

165. The SNMMI and EANM Practice Guideline for Renal Scintigraphy in Adults

, yields very low-quality images with a high radiation dose and is 153 no longer used. 154 99m-Tc-MAG3 (Fritzberg AR, et al, 1986), is similar to OIH (Russell, 1999), although it has very 155 little glomerular filtration due to its high plasma protein binding, resulting in a lower extraction 156 fraction. (Muller-Suur, 1989). 99m-Tc-MAG3 is currently the most frequently used renal tubular 157 agent in nuclear medicine practice. Since its excretion is directly related to proximal tubular 158 function (...) (i.e., 60% of PAH on average), Bubeck et al. proposed the concept of tubular extraction 159 rate (TER) (Bubeck B, et al, 1987) to replace the term ERPF. 160 161 99m-Tc-DTPA is excreted by glomerular filtration without renal tubular secretion the renal 162 clearance is slightly lower than inulin, and it was first used clinically in 1970 (Hauser W. et al 163 1970). There is about 5-10% protein bound DTPA in the plasma after one hour. DTPA labelled 164 with 99m-Tc remains the most suitable

2019 Society of Nuclear Medicine and Molecular Imaging

167. WHO Guidelines for the pharmacological and radiotherapeutic management of cancer pain in adults and adolescents

AND RADIOTHERAPEUTIC MANAGEMENT OF CANCER PAIN IN ADULTS AND ADOLESCENTS 6.4.2. Antidepressants 39 6.4.3. Anticonvulsants 40 6.5. Management of bone pain 41 6.5.1. Bisphosphonates 41 6.5.2. Monoclonal antibodies 44 6.5.3. Comparison of bisphosphonates or monoclonal antibodies 45 6.5.4. Single-fraction radiotherapy compared with high-fractionated radiotherapy 46 6.5.5. Radioisotopes for bone pain 48 7 . RESEARCH AGENDA 50 Interests declared by persons involved in guideline development 51 Funding sources 51

2019 World Health Organisation Guidelines

168. Iron Deficiency and Anaemia in Adults

, and the recycling of iron after red blood cell (RBC) degradation. Under normal physiological conditions, as there is no active iron excretion mechanism, iron homeostasis is strictly controlled at the level of intestinal absorption. Storage of iron In healthy individuals, about 25% of the total body iron (800 to 1,000mg) represents storage iron, mainly as ferritin in the liver and skeletal muscle; consequently, serum ferritin is a useful marker for iron stores. Hepcidin is a naturally occurring protein, secreted (...) preparations contain varying amounts of ferrous iron and the frequency of gastrointestinal side effects related to each different preparation tends to be directly related to the content of ferrous iron. Iron salt Dose Preparation Content of ferrous iron Ferrous sulphate 200mg tablets 65mg Ferrous gluconate 300mg tablets 35mg Sodium feredetate (Sytron) 380mg/ 10mls elixir 55mg Limitations to iron supplements There are several limitations to taking iron supplements. Only a small amount is actually absorbed

2018 Royal College of Nursing

171. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease

by consideration of a sodium-glucose cotransporter 2 inhibitor or a glucagon-like peptide-1 receptor agonist. 7. All adults should be assessed at every healthcare visit for tobacco use, and those who use tobacco should be assisted and strongly advised to quit. 8. Aspirin should be used infrequently in the routine primary prevention of ASCVD because of lack of net benefit. 9. Statin therapy is first-line treatment for primary prevention of ASCVD in patients with elevated low- density lipoprotein cholesterol (...) electronic nicotine delivery systems FDA U.S. Food and Drug Administration GLP-1R glucagon-like peptide-1 receptor HbA1c hemoglobin A1c HDL-C high-density lipoprotein cholesterol HbA1c hemoglobin A1c LDL-C low-density lipoprotein cholesterol MI myocardial infarction PCE pooled cohort equations RCT randomized controlled trial SBP systolic blood pressure SGLT-2 sodium-glucose cotransporter 2 T2DM type 2 diabetes mellitus USPSTF U.S. Preventive Services Task Force Downloaded from http://ahajournals.org

2019 American Heart Association

172. Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, and Treatment Strategies

(including in patients with HF with preserved ejection fraction [HFpEF]), thus underscoring the influence of RV function on renal hemodynamics. However, data on the neurohumoral perturbations and sodium and water retention in isolated RV failure models in humans are scarce. Early experimental models inducing RV failure by graded valvular damage showed a decrease in renal blood flow, preserved GFR, and intense salt and water retention. Other investigators have shown that despite the presence of pulmonary (...) or even elevated blood pressure and normal left ventricular (LV) ejection fraction (EF). The kidneys are not first in line for delivery of oxygenated blood, yet they receive a disproportionately large fraction (25%) of cardiac output (CO) because they are a low-resistance circuit. The difference between arterial driving pressure and venous outflow pressures must remain sufficiently large for adequate renal blood flow and glomerular filtration. In this context, the concept of elevated central venous

2019 American Heart Association

173. Primary Prevention of Cardiovascular Disease

with type 2 diabetes mellitus, lifestyle changes, such as improving dietary habits and achieving exercise recommendations, are crucial. If medication is indicated, metformin is first-line therapy, followed by consideration of a sodium-glucose cotransporter 2 inhibitor or a glucagon-like peptide-1 receptor agonist. 7. All adults should be assessed at every healthcare visit for tobacco use, and those who use tobacco should be assisted and strongly advised to quit. 8. Aspirin should be used infrequently (...) electronic nicotine delivery systems FDA U.S. Food and Drug Administration GLP-1R glucagon-like peptide-1 receptor HbA1c hemoglobin A1c HDL-C high-density lipoprotein cholesterol HbA1c hemoglobin A1c LDL-C low-density lipoprotein cholesterol MI myocardial infarction PCE pooled cohort equations RCT randomized controlled trial SBP systolic blood pressure SGLT-2 sodium-glucose cotransporter 2 T2DM type 2 diabetes mellitus USPSTF U.S. Preventive Services Task Force 1 MANUSCRIPT ACCEPTED ACCEPTED MANUSCRIPT

2019 American College of Cardiology

174. Radiology and Nuclear Medicine Studies in Lactating Women

and Lactation Database (LactMed) [Internet] . Bethesda (MD): National Library of Medicine (US); 2006 -. Sodium Iodide I 131. Updated October 31, 2018. Available at (accessed April 22 , 2019 ). 33. Romney B , Nickoloff EL , Esser PD . Excretion of radioiodine in breast milk . J Nucl Med 1989 ;30:124–126. , 34. Leide-Svegborn S , Ahlgren L , Johansson L, et al. Excretion of radionuclides in human breast milk after nuclear medicine examinations. Biokinetic and dosimetric data and recommendations (...) of iodinated contrast When iodinated contrast is administered through nonvascular routes, systemic absorption of these contrast agents is low and has few known adverse reactions. However, there are reports of anaphylactoid-like reactions with these agents, so some degree of systemic absorption can occur. With enteral administration (e.g., oral or rectal), excretion is through the fecal route and is dependent on bowel transit time. Intracavity (e.g., hysterosalpingography) or intravesical (e.g., cystography

Full Text available with Trip Pro

2019 Academy of Breastfeeding Medicine

175. Peramivir (Alpivab) - Influenza, Human

. In the rabbit, at IV doses =200 mg/kg/day, following dosing from 1-9 days duration, the kidney was identified as the target organ for toxicity, with increased BUN and creatinine and increased ratios of excreted sodium and chloride compared to creatinine. Microscopically, mild to marked acute tubular necrosis was observed (in some studies “nephrosis”) which generally occurred at exposure (AUC) values of > 1,130,000 nghr/mL. Several additional nephrotoxicity studies were conducted to more thoroughly evaluate (...) that it is not more effective than licensed agents. Overall, it was concluded that peramivir would not address a clear unmet medical need and it was regarded as being of limited relevance for public health. 2.2. Quality aspects 2.2.1. Introduction The finished product is presented as a concentrate for solution for infusion containing 200 mg of peramivir as active substance per vial. 1 mL concentrate for solution for infusion contains 10 mg peramivir (anhydrous base). Other ingredients are: sodium chloride, water

2018 European Medicines Agency - EPARs

176. Velmanase alfa (Lamzede) - alpha-Mannosidosis

(WFI) prior to use. The reconstituted finished product is a colourless liquid of pH 7.5 ± 0.5. The strength of the reconstituted finished product is 2 mg/mL. Other ingredients are disodium phosphate dihydrate, sodium dihydrogen phosphate dihydrate, mannitol and glycine. The product is available in a 10 ml vial (Type I glass) with a bromobutyl rubber stopper, an aluminium seal and a polypropylene flip off cap. 2.2.2. Active Substance 2.2.2.1. General Information Genetic deficiency of lysosomal alpha (...) . At the end of the production stage, the supernatant is harvested by centrifugation and clarified by depth filtration and finally filtered through a bioburden reduction filter. Assessment report EMA/205473/2018 Page 12/109 The purification process starting from clarified culture supernatant contains four chromatographic steps. The active substance bulk is formulated in a sodium phosphate/glycine/ D-Mannitol buffer. The container closure consists of a sterile bag. Sufficient information on the container

2018 European Medicines Agency - EPARs

177. Patients Hospitalized with Heart Failure: Risk Assessment, Management, and Clinical Trajectory

chain; ARB¼ angiotensin receptor blockers; ATTR¼ amyloid transthyretin; GDMT¼ guideline-directed medical therapy; HF¼ heart failure; HFrEF¼ heart failure with reduced ejection fraction; HTN¼ hypertension; RAAS¼ renin-angiotensin-aldosterone system; SGLT2¼ sodium-glucose cotransporter-2; STEMI¼ ST-segment elevation myocardial infarction. JACC VOL. -,NO. -,2019 Hollenberg et al. -,2019:-–- Heart Failure Hospitalization Pathway 11trial databases are continuous variables, while those from administrative (...) BUN (49,62) High BUN at discharge increases risk (66). n Low spot urine sodium after ?rst IV diuretic dose (114) Low total urinary sodium excretion may be a more important marker than total urine output during hospitalization (121). n Diuretic resistance with high outpatient doses (115–117) Diuretic resistance in-hospital associated with longer LOS and worse outcomes (66,77). High risk if discharged on high loop diuretic doses (66,115–117). Degree of congestion at admission not predictive

2019 American College of Cardiology

178. BTS/SIGN British Guideline on the Management of Asthma

structured clinical assessment, 3.4 Organisation of diagnostic services 4 Monitoring asthma New: Table 7, 4.1 Targeting care, 4.2 Monitoring current asthma symptom control, 4.3 Predicting future risk of asthma attacks, 4.3.1 Adults, 4.3.2 School-aged children, 4.3.3 Preschool children, 4.3.4 People with severe asthma, 4.4 Physiological measures, 4.4.1 Spirometry and peak expiratory flow, 4.4.2 Fractional exhaled nitric oxide, 4.4.3 Eosinophils, 4.5 Other approaches 5 Supported self management New: 5.2.3

2019 British Thoracic Society

179. Cardiovascular Outcome Trials for Type 2 Diabetes

Cardiovascular Outcome Trials for Type 2 Diabetes Cardiovascular Outcome Trials for Type 2 Diabetes | CADTH.ca CADTH Document Viewer Cardiovascular Outcome Trials for Type 2 Diabetes Table of Contents Search this document Cardiovascular Outcome Trials for Type 2 Diabetes June 2019 Summary Dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose cotransporter-2 (SGLT-2) inhibitors, and glucagon-like peptide-1 (GLP-1) receptor agonists are classes of medications used in diabetes mellitus (DM (...) - Published November 2016 Yes Yes ADA = American Diabetes Association; EASD = European Association for the Study of Diabetes; DPP-4 = dipeptidyl peptidase-4; GLP-1 = glucagon-like peptide-1; SGLT-2 = sodium-glucose cotransporter-2. a The active ingredient is available in Canada, but the dosage form studied in this trial is not. See the Concurrent Developments section of this bulletin for more information. The Technology A number of DPP-4 inhibitors, SGLT-2 inhibitors, and GLP-1 receptor agonists have been

2019 CADTH - Issues in Emerging Health Technologies

180. Axicabtagene ciloleucel (Yescarta) - diffuse large B-cell lymphoma (DLBCL); primary mediastinal large B-cell lymphoma (PMBCL)

Each bag of YESCARTA contains 300 mg sodium. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Dispersion for infusion. A clear to opaque, white to red dispersion. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications YESCARTA is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL), after two or more lines of systemic therapy. 4.2 Posology and method (...) not be used. • Central venous access is recommended for the administration of YESCARTA. • The patient’s identity must be verified again to match the patient identifiers on the YESCARTA bag. • The tubing should be primed with 0.9% sodium chloride solution (0.154 mmol sodium per ml) prior to infusion. • Entire contents of the YESCARTA bag should be infused within 30 minutes by either gravity or a peristaltic pump. YESCARTA is stable at room temperature for up to 3 hours after thaw. • The bag should

2018 European Medicines Agency - EPARs

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>